Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Chia Tai Tianqing Pharmaceutical Group Co: Clinical Trials & FDA Approval Profile

Chia Tai Tianqing Pharmaceutical Group Co (Global / Institutional) sponsors 156 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 44 active protocols (23 recruiting now), 18 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)12.8%
Median Closed Enrollment vs National (145 pts)47 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Chia Tai Tianqing Pharmaceutical Group Co
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)156
Active Pipeline (Recruiting Now)44 (23)
Completed vs Stopped Early18 / 20 (12.8%)
Median Closed Actual Enrollment47 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Chia Tai Tianqing Pharmaceutical Group Co
Hospital Research SiteLocationShared Protocols
Hunan Cancer HospitalChangsha, Hunan35
The First Hospital of Jilin UniversityChangchun, Jilin32
Henan Cancer HospitalZhengzhou, Henan27

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Chia Tai Tianqing Pharmaceutical Group Co
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT06900920A Study of TQB3473 Tablets Compared to Placebo in the Treatment of Adult Primary Immune ThrombocytopeniaPhase IIIRECRUITING
NCT06300320A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host DiseasePhase IIRECRUITING
NCT06351150Efficacy and Safety of Angiotensin II Injection Versus Placebo in Patients With Refractory Distributed ShockPhase IIIRECRUITING
NCT07512596Study on the Safety and Efficacy of Polymyxin E2 Methanesulfonate for Injection in the Treatment of Hospital-Acquired Bacterial Pneumonia/VePhase IIRECRUITING
NCT07551427A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105 Tablets in Subjects With Intermediate/High-risk MyelofibrPhase IIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Chia Tai Tianqing Pharmaceutical Group Co Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI